ARTICLE | Clinical News
Eisai's Lenvima gets Priority Review for HCC in China
January 5, 2018 10:14 PM UTC
Eisai Co. Ltd. (Tokyo:4523) said China FDA granted Priority Review to an NDA for Lenvima lenvatinib mesylate (Kisplyx - EU, E7080) to treat hepatocellular carcinoma (HCC). The company submitted the NDA in October 2017...